Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Melan-A-specific CD8+ T cells + MELOE-1-specific CD8+ T cells
- Development stage
- Phase 2
- Lead developer
- Nantes University Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational adoptive cell therapy (ACT) consists of a combination of autologous CD8+ T cell clones specific for two distinct melanoma-associated antigens: Melan-A (also known as MART-1) and MELOE-1. Developed primarily by researchers at the University of Nantes and Inserm, this approach aims to enhance the anti-tumor immune response in patients with metastatic melanoma. Melan-A is a well-characterized melanocytic differentiation antigen, while MELOE-1 is a melanoma-overexpressed antigen encoded by a polycistronic transcript (MELOE). By co-infusing T cells targeting both antigens, the therapy seeks to minimize the risk of tumor immune escape through antigen loss or heterogeneity. The process involves isolating specific T-cell clones from the patient's peripheral blood or tumor-infiltrating lymphocytes, expanding them ex vivo, and re-infusing them following a lymphodepleting conditioning regimen.
- Other names
- MART-1-specific CD8+ T cells + MELOE-1-specific CD8+ T cellsMelan-A and MELOE-1 specific T cell clonesMelan-A/MELOE-1 specific CD8+ T cells
02
Targets
MELOE1 (Melanoma-expressed antigen 1 peptide presented by HLA-A*02:01)MART-1/HLA-A*02:01 (Melanoma-associated antigen (Melanoma antigen recognized by T cells 1, Melanocyte protein PMEL, Tyrosinase) peptide-HLA-A*02:01 complex)
Beyond the preview
Go deeper on Melan-A-specific CD8+ T cells + MELOE-1-specific CD8+ T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Melan-A-specific CD8+ T cells + MELOE-1-specific CD8+ T cells.